6/11/26
Top 10 emerging gene therapies – with the highest success potential
Identified by Explority AI across 5,846 rare diseases
FDA releases draft guidance to accelerate gene therapy development
That matters most for rare diseases, where building a full program from the ground up can be economically unviable. The guidance lets sponsors reuse prior evidence in three places:
borrow results from earlier vector studies in quality-control procedures
transfer data from past nonclinical studies, avoiding repeat animal studies
cite clinical dosing and response data from similar platforms
In all cases, sponsors should provide a scientific rationale demonstrating the applicability of the data being leveraged to their specific product and development context. The draft guidance is available for public comment.
“By outlining how sponsors can intelligently build upon existing nonclinical, clinical, and manufacturing knowledge, we can meaningfully streamline development programs and lower the cost barriers that have historically slowed access to these potentially life-changing treatments.” – Vijay Kumar, CBER.
Top 10 emerging gene therapies – with highest success potential
At Explority, we trained LLMs that forecast the probability of success for early-stage therapies described in published research. With 3,718 novel gene therapy programs monitored across 5,846 rare diseases, we share the 10 with the highest success potential in clinical trials:
ready to solve rare diseases?
Partner with Explority to turn information into impact. Whether you're planning your next phartership, selecting next R&D idea or just have questions—drop us a message. Let’s explore how we can work together to solve rare diseases.
